Clinical TrialID 1245
Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI
NCT05594355
Mild Cognitive Impairment (MCI)
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Herb: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 1245
- Evidence Id
- 1245
- Core Evidence Id
- 1245
- Source Clinical Trial Id
- 1227
- Herb2 Clinical Trial Id
- HBCT001227
- Nct Id
- NCT05594355
- Title
- Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI
- Status
- Active_Not_Recruiting
- Phase
- Phase 4
- Study Result
- No
- Study Condition
- Mild Cognitive Impairment (MCI)
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: TEBOFORTAN
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 100
- Outcome Measure
- Compare changes in blood marker levels of inflammation and oxidation, To compare the changes in the levels of blood markers of inflammation and oxidation between the baseline visit and the follow-up visits at 6 and 12 months between the study group (patients with mild cognitive impairment who receive treatment with 1 daily tablet of EGb 761® 240 mg orally) and the control group (patients with the same clinical characteristics without treatment with EGb 761®). Blood markers of inflammation and oxidation: in v0 (baseline), v1 (6 month), v2 (12 month). The panel of inflammation markers from Olink proteomics (https://www.olink.com/products/inflammation/) will be used with 92 proteins associated with inflammatory diseases and related biological processes. The blood samples of the participants will be collected in the Fundació ACE Nursing Unit and sent to Olink proteomics for further analysis, Between the baseline visit and follow-up visits at 6 and 12 months. All procedures in each of the visits will be carried out in a maximum period of 30 days.
- Sponsor Collaborator
- Fundació ACE Institut Català de Neurociències Aplicades
- Funded By
- OTHER
- Location
- Fundació ACE. Institut Català de Neurociències Aplicades., Barcelona, 08028, Spain
- Other Id
- ACE-2020-EGb761
- Start Date
- 2021-04-16
- Primary Completion Date
- 2023-12
- Completion Date
- 2023-12
- First Posted
- 2022-10-26
- Results First Posted
- Last Update Posted
- 2023-02-15
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05594355
- Title Cn
- Title En
- Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI
- Bilingual Status
- semi_complete